Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

GLAND's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 0.000000
forwardPE 26.278519
debtToEquity 3.428000
earningsGrowth 0.498000
revenueGrowth 0.074000
grossMargins 0.577280
operatingMargins 0.177140
trailingEps 46.790000
forwardEps 65.010000

GLAND's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
GLAND's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.

Price projections:

Price projections for GLAND
Price projections for GLAND

The steady upward revision of Gland Pharma Limited's price projections indicates growing confidence in the company's performance. Analysts are becoming increasingly optimistic about Gland Pharma Limited's future prospects and potential for growth.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


There were 3 Gland Pharma Limited sales transactions, at market price of 1821.2833251953125.Throughout the period under consideration, there were no sell transactions.The trend of more buys than sells at GLAND's current price levels suggests a possible bullish sentiment. This could indicate that investors are expecting a favorable outlook for the stock, prompting more buying activity.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


GLAND has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as GLAND is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.